Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays

• Published in: mSphere Vol. 7; no. 1; p. e0095321
• Main Authors: Bibby, David C, Savanovic, Michael, Zhang, Jinrong, Torelli, Alessandro, Jeeninga, Rienk E, Gagnon, Luc, Harris, Shannon L
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 23.02.2022
• Subjects: Antibodies, Viral; Epidemiology; Erythrocytes; Hemagglutination; Hemagglutination inhibition; hemagglutination inhibition assay; Hemagglutination Inhibition Tests - methods; Humans; Influenza; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Laboratories; precision; Regulatory approval; Reproducibility; Reproducibility of Results; Research Article; Serology; Standardization; Testing laboratories; Vaccines; Viruses; influenza; hemagglutination inhibition assay; HI; reproducibility; precision
• ISSN: 2379-5042; 2379-5042
• DOI: 10.1128/msphere.00953-21

The hemagglutination inhibition (HI) assay is a prominent and commonly accepted method used to determine quantitative antibody titers for influenza virus. However, the reproducibility and consistency of this assay may be affected by several factors, including its reliance on biological reagents that are difficult to standardize, such as red blood cells. This report assesses HI assay performance across three accredited, global laboratories when using test virus and a human serum panel aliquoted and distributed from a centrally located reagent stock. The panel of human sera comprised samples with expected low, medium, and high HI titers against two influenza viruses: A/H1N1/California/07/2009 and B/Victoria/Brisbane/60/2008. HI analysis followed a consensus test protocol. Overall, the HI assay reproducibility within each laboratory was high for both influenza strains, with a within-assay run and intraday precision of 100%. Interlab reproducibility was assessed by comparing the geometric mean titer (GMT) of each sample at each laboratory to the consensus GMT of the sample. A/H1N1 had 100% interlab reproducibility, and none of the individual laboratory GMT values exceeded a 2-fold difference compared to the consensus GMT in any tested sample. B/Victoria had an overall reproducibility of 83%. The results demonstrate that with standardization of key reagents and the use of a common protocol by trained staff, the biologically based HI assay can provide similar results between geographically dispersed laboratories. Licensure of influenza vaccines relies on the hemagglutination inhibition (HI) assay as the primary method to determine quantitative functional antibody titers. The HI assay is also widely used for influenza virus surveillance, characterization, and epidemiology studies. However, the HI assay has a notable lack of reproducibility and consistency. If serology results are required from multiple concurrent studies supporting the development and regulatory approval of a product, the testing capacity of any given testing laboratory may be exceeded and data from more than one testing laboratory included in regulatory filings. Thus, understanding the reproducibility of HI assay results over time and between testing laboratories is necessary to support a robust clinical trial serology data set. Our results demonstrate that with standardization of key reagents and use of a common protocol by experienced and trained staff, the biologically based HI assay can provide similar results between geographically dispersed laboratories.